Grazia Aleppo, Anders L. Carlson, Janet B. McGill, Hamza Alshannaq, Rodolfo J. Galindo, Davida Kruger, Carol J. Levy, Jéssica Yumi Matuoka, Sabrina Ilham, Guillermo Umpierrez, Gregory J. Norman
We report evidence that supports the use of this technology in people with T2D not using insulin.
Continuous glucose monitoring (CGM) technology is becoming increasingly available to people with diabetes using insulin therapy; however, availability for people with type 2 diabetes (T2D) not on insulin remains limited. For people with T2D, there is strong evidence of glycemic benefit with CGM use for those treated with insulin, and CGM is accepted as standard of care. This review explores the impact of CGM use on glycemic and patient-reported outcomes in noninsulin treated populations with T2D, reporting outcomes from 10 identified randomized controlled trials and 15 nonrandomized studies. We report evidence that supports the use of this technology in people with T2D not using insulin.